The tyrosine kinase inhibitor imatinib mesylate delays prion neuroinvasion by inhibiting prion propagation in the periphery

References

• Aguzzi A, Heikenwalder M. Prions, cytokines, and chemokines: a meeting in lymphoid organs. Immunity 2005; 22: 145–154
   PubMed Web of Science ®Google Scholar
• Blattler T, Brandner S, Raeber A J, Klein M A, Voigtlander T, Weissmann C, Aguzzi A. PrP-expressing tissue required for transfer of scrapie infectivity from spleen to brain. Nature 1997; 389: 69–73
   PubMed Web of Science ®Google Scholar
• Brain J, Saksena A, Laneuville P. The kinase inhibitor STI571 reverses the Bcr-Abl induced point mutation frequencies observed in pre-leukemic P190(Bcr-Abl) transgenic mice. Leuk Res 2002; 26: 1011–1016
   PubMed Web of Science ®Google Scholar
• Buday L. Membrane-targeting of signalling molecules by SH2/SH3 domain-containing adaptor proteins. Biochim Biophys Acta 1999; 1422: 187–204
   PubMed Web of Science ®Google Scholar
• Budka H. Neuropathology of prion diseases. Br Med Bull 2003; 66: 121–130
   PubMed Web of Science ®Google Scholar
• Bueler H, Aguzzi A, Sailer A, Greiner R A, Autenried P, Aguet M, Weissmann C. Mice devoid of PrP are resistant to scrapie. Cell 1993; 73: 1339–1347
   PubMed Web of Science ®Google Scholar
• Bujassoum S, Rifkind J, Lipton J H. Isolated central nervous system relapse in lymphoid blast crisis chronic myeloid leukemia and acute lymphoblastic leukemia in patients on imatinib therapy. Leuk Lymphoma 2004; 45: 401–403
   PubMed Web of Science ®Google Scholar
• Capdeville R, Buchdunger E, Zimmermann J, Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 2002; 1: 493–502
   PubMed Web of Science ®Google Scholar
• Cashman N R, Caughey B. Prion diseases—close to effective therapy?. Nat Rev Drug Discov 2004; 3: 874–884
   PubMed Web of Science ®Google Scholar
• Chesebro B, Trifilo M, Race R, Meade-White K, Teng C, La Casse R, Raymond L, Favara C, Baron G, Priola S, Caughey B, Masliah E, Oldstone M. Anchorless prion protein results in infectious amyloid disease without clinical scrapie. Science 2005; 308: 1435–1439
   PubMed Web of Science ®Google Scholar
• Criado J R, Sanchez-Alavez M, Conti B, Giacchino J L, Wills D N, Henriksen S J, Race R, Manson J C, Chesebro B, Oldstone M B. Mice devoid of prion protein have cognitive deficits that are rescued by reconstitution of PrP in neurons. Neurobiol Dis 2005; 19: 255–265
   PubMed Web of Science ®Google Scholar
• Crossman L C, Druker B J, Deininger M W, Pirmohamed M, Wang L, Clark R E. hOCT 1 and resistance to imatinib. Blood 2005; 106: 1133–1134
   PubMed Web of Science ®Google Scholar
• Dai H, Marbach P, Lemaire M, Hayes M, Elmquist W F. Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J Pharmacol Exp Ther 2003; 304: 1085–1092
   PubMed Web of Science ®Google Scholar
• Decaudin D, de Cremoux P, Sastre X, Judde J G, Nemati F, Tran-Perennou C, Freneaux P, Livartowski A, Pouillart P, Poupon M F. In vivo efficacy of STI571 in xenografted human small cell lung cancer alone or combined with chemotherapy. Int J Cancer 2005; 113: 849–856
   PubMed Web of Science ®Google Scholar
• Doh-ura K, Ishikawa K, Murakami-Kubo I, Sasaki K, Mohri S, Race R, Iwaki T. Treatment of transmissible spongiform encephalopathy by intraventricular drug infusion in animal models. J Virol 2004; 78: 4999–5006
   PubMed Web of Science ®Google Scholar
• Ertmer A, Gilch S, Yun S W, Flechsig E, Klebl B, Stein-Gerlach M, Klein M A, Schatzl H M. The tyrosine kinase inhibitor STI571 induces cellular clearance of PrPSc in prion-infected cells. J Biol Chem 2004; 279: 41918–41927
   PubMed Web of Science ®Google Scholar
• Glatzel M, Heppner F L, Albers K M, Aguzzi A. Sympathetic innervation of lymphoreticular organs is rate limiting for prion neuroinvasion. Neuron 2001; 31: 25–34
   PubMed Web of Science ®Google Scholar
• Green R M, Lo K, Sterritt C, Beier D R. Cloning and functional expression of a mouse liver organic cation transporter. Hepatology 1999; 29: 1556–1562
   PubMed Web of Science ®Google Scholar
• Heikenwalder M, Zeller N, Seeger H, Prinz M, Klohn P C, Schwarz P, Ruddle N H, Weissmann C, Aguzzi A. Chronic lymphocytic inflammation specifies the organ tropism of prions. Science 2005; 307: 1107–1110
   PubMed Web of Science ®Google Scholar
• Honey K, Rudensky A Y. Lysosomal cysteine proteases regulate antigen presentation. Nat Rev Immunol 2003; 3: 472–482
   PubMed Web of Science ®Google Scholar
• Jones S B, Lu H Y, Lu Q. Abl tyrosine kinase promotes dendrogenesis by inducing actin cytoskeletal rearrangements in cooperation with Rho family small GTPases in hippocampal neurons. J Neurosci 2004; 24: 8510–8521
   PubMed Web of Science ®Google Scholar
• Jonker J W, Schinkel A H. Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3). J Pharmacol Exp Ther 2004; 308: 2–9
   PubMed Web of Science ®Google Scholar
• Kaeser P S, Klein M A, Schwarz P, Aguzzi A. Efficient lymphoreticular prion propagation requires PrP(c) in stromal and hematopoietic cells. J Virol 2001; 75: 7097–7106
   PubMed Web of Science ®Google Scholar
• Kimberlin R H, Walker C A. Incubation periods in six models of intraperitoneally injected scrapie depend mainly on the dynamics of agent replication within the nervous system and not the lymphoreticular system. J Gen Virol 1988; 69: 2953–2960, (Pt 12)
   PubMed Web of Science ®Google Scholar
• Klein M A, Kaeser P S, Schwarz P, Weyd H, Xenarios I, Zinkernagel R M, Carroll M C, Verbeek J S, Botto M, Walport M J, Molina H, Kalinke U, Acha-Orbea H, Aguzzi A. Complement facilitates early prion pathogenesis. Nat Med 2001; 7: 488–492
   PubMed Web of Science ®Google Scholar
• Leis J F, Stepan D E, Curtin P T, Ford J M, Peng B, Schubach S, Druker B J, Maziarz R T. Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI–571). Leuk Lymphoma 2004; 45: 695–698
   PubMed Web of Science ®Google Scholar
• Li A, Harris D A. Mammalian prion protein suppresses Bax-induced cell death in yeast. J Biol Chem 2005; 280: 17430–17434
   PubMed Web of Science ®Google Scholar
• Luhr K M, Nordstrom E K, Low P, Ljunggren H G, Taraboulos A, Kristensson K. Scrapie protein degradation by cysteine proteases in CD11c+ dendritic cells and GT1-1 neuronal cells. J Virol 2004; 78: 4776–4782
   PubMed Web of Science ®Google Scholar
• Mahon F X, Belloc F, Lagarde V, Chollet C, Moreau-Gaudry F, Reiffers J, Goldman J M, Melo J V. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 2003; 101: 2368–2373
   PubMed Web of Science ®Google Scholar
• Montrasio F, Frigg R, Glatzel M, Klein M A, Mackay F, Aguzzi A, Weissmann C. Impaired prion replication in spleens of mice lacking functional follicular dendritic cells. Science 2000; 288: 1257–1259
   PubMed Web of Science ®Google Scholar
• Mouillet-Richard S, Ermonval M, Chebassier C, Laplanche J L, Lehmann S, Launay J M, Kellermann O. Signal transduction through prion protein. Science 2000; 289: 1925–1928
   PubMed Web of Science ®Google Scholar
• Netzer W J, Dou F, Cai D, Veach D, Jean S, Li Y, Bornmann W G, Clarkson B, Xu H, Greengard P. Gleevec inhibits beta-amyloid production but not Notch cleavage. Proc Natl Acad Sci U S A 2003; 100: 12444–12449
   PubMed Web of Science ®Google Scholar
• Nico P B, de-Paris F, Vinade E R, Amaral O B, Rockenbach I, Soares B L, Guarnieri R, Wichert-Ana L, Calvo F, Walz R, Izquierdo I, Sakamoto A C, Brentani R, Martins V R, Bianchin M M. Altered behavioural response to acute stress in mice lacking cellular prion protein. Behav Brain Res 2005; 162: 173–181
   PubMed Web of Science ®Google Scholar
• Peretz D, Williamson R A, Kaneko K, Vergara J, Leclerc E, Schmitt-Ulms G, Mehlhorn I R, Legname G, Wormald M R, Rudd P M, Dwek R A, Burton D R, Prusiner S B. Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature 2001; 412: 739–743
   PubMed Web of Science ®Google Scholar
• Prinz M, Heikenwalder M, Junt T, Schwarz P, Glatzel M, Heppner F L, Fu Y X, Lipp M, Aguzzi A. Positioning of follicular dendritic cells within the spleen controls prion neuroinvasion. Nature 2003; 425: 957–962
   PubMed Web of Science ®Google Scholar
• Prusiner S B. Prions. Proc Natl Acad Sci U S A 1998; 95: 13363–13383
   PubMed Web of Science ®Google Scholar
• Roucou X, Gains M, LeBlanc A C. Neuroprotective functions of prion protein. J Neurosci Res 2004; 75: 153–161
   PubMed Web of Science ®Google Scholar
• Safar J G, DeArmond S J, Kociuba K, Deering C, Didorenko S, Bouzamondo-Bernstein E, Prusiner S B, Tremblay P. Prion clearance in bigenic mice. J Gen Virol 2005; 86: 2913–2923
   PubMed Web of Science ®Google Scholar
• Schmitt A, Mossner R, Gossmann A, Fischer I G, Gorboulev V, Murphy D L, Koepsell H, Lesch K P. Organic cation transporter capable of transporting serotonin is up-regulated in serotonin transporter-deficient mice. J Neurosci Res 2003; 71: 701–709
   PubMed Web of Science ®Google Scholar
• Schwartzberg P L, Stall A M, Hardin J D, Bowdish K S, Humaran T, Boast S, Harbison M L, Robertson E J, Goff S P. Mice homozygous for the ablm1 mutation show poor viability and depletion of selected B and T cell populations. Cell 1991; 65: 1165–1175
   PubMed Web of Science ®Google Scholar
• Spielhaupter C, Schatzl H M. PrPC directly interacts with proteins involved in signaling pathways. J Biol Chem 2001; 276: 44604–44612
   PubMed Web of Science ®Google Scholar
• Supattapone S, Nguyen H O, Cohen F E, Prusiner S B, Scott M R. Elimination of prions by branched polyamines and implications for therapeutics. Proc Natl Acad Sci U S A 1999; 96: 14529–14534
   PubMed Web of Science ®Google Scholar
• Supattapone S, Wille H, Uyechi L, Safar J, Tremblay P, Szoka F C, Cohen F E, Prusiner S B, Scott M R. Branched polyamines cure prion-infected neuroblastoma cells. J Virol 2001; 75: 3453–3461
   PubMed Web of Science ®Google Scholar
• Takayama N, Sato N, O'Brien S G, Ikeda Y, Okamoto S. Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid. Br J Haematol 2002; 119: 106–108
   PubMed Web of Science ®Google Scholar
• Thomas J, Wang L, Clark R E, Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004; 104: 3739–3745
   PubMed Web of Science ®Google Scholar
• Tybulewicz V L, Crawford C E, Jackson P K, Bronson R T, Mulligan R C. Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene. Cell 1991; 65: 1153–1163
   PubMed Web of Science ®Google Scholar
• Wang H, Cheng F, Cuenca A, Horna P, Zheng Z, Bhalla K, Sotomayor E M. Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance. Blood 2005; 105: 1135–1143
   PubMed Web of Science ®Google Scholar
• Weissmann C, Aguzzi A. Approaches to therapy of prion diseases. Annu Rev Med 2005; 56: 321–344
   PubMed Web of Science ®Google Scholar
• Wolff N C, Richardson J A, Egorin M, Ilaria R L, Jr. The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia. Blood 2003; 101: 5010–5013
   PubMed Web of Science ®Google Scholar
• Woodring P J, Hunter T, Wang J Y. Regulation of F-actin-dependent processes by the Abl family of tyrosine kinases. J Cell Sci 2003; 116: 2613–2626
   PubMed Web of Science ®Google Scholar
• Yun S W, Gerlach M, Riederer P, Klein M A. Oxidative stress in the brain at early preclinical stages of mouse scrapie. Exp Neurol 2006; 201: 90–98
   PubMed Web of Science ®Google Scholar